Business context and reporting period
Protalix Biotherapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2021 (not a standalone fourth-quarter report). The company develops and manufactures recombinant therapeutic proteins using its ProCellEx plant-cell platform. Its marketed product, Elelyso (taliglucerase alfa), is licensed to Pfizer outside Brazil; the company retains Brazilian rights. Lead candidate PRX-102 is in development for Fabry disease, with PRX-115 and PRX-119 at preclinical stages.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $38.4 million | $62.9 million |
| Revenue from product sales | $16.7 million | $16.2 million |
| License and R&D services revenue | $21.6 million | $46.7 million |
| Cost of goods sold | $16.3 million | $10.9 million |
| R&D expense, net | $29.7 million | $38.2 million |
| SG&A expense | $12.7 million | $11.1 million |
| Operating income (loss) | $(20.5) million | $2.7 million |
| Net income (loss) | $(27.6) million | $(6.5) million |
| Net cash used in operations | $(10.3) million | $(26.1) million |
| Cash and cash equivalents at year-end | $39.0 million | $18.3 million |
Total revenue less reported cost of goods sold was $22.0 million; this is not a product-only gross margin because revenue includes license and R&D services. The filing reports no separate margin measure. At December 31, 2021, total assets were $73.7 million and total liabilities were $79.7 million. The company had $28.75 million principal amount of 7.5% secured convertible notes due in 2024; the notes are secured by liens on company assets, including intellectual property. Their net carrying amount was $27.9 million. The indenture requires at least $7.5 million of cash; the company reported compliance at year-end.
Material changes versus the prior comparable period
- Total revenue fell 39%, primarily as license and R&D services revenue from Chiesi declined; product-sales revenue increased 3%. Pfizer sales rose $2.1 million, partly offset by a $1.6 million decline in Brazil sales.
- Operating results swung from $2.7 million of operating income to a $20.5 million operating loss. Cost of goods sold rose 50%, including one-time manufacturing preparation costs and higher manufacturing costs.
- Net loss widened to $27.6 million from $6.5 million. R&D expense declined 22%, mainly following completion of PRX-102 Phase III trials; SG&A increased 14%, primarily from insurance-related corporate costs.
- Operating cash use improved to $10.3 million from $26.1 million, helped by a $13.2 million increase in contract liabilities. Cash increased by $20.7 million during 2021.
Outlook, commentary, risks and unusual items
- The FDA issued a Complete Response Letter for PRX-102 in April 2021. It identified the need for an inspection of the Carmiel manufacturing facility and follow-up on items at the European fill-and-finish facility; the letter did not identify safety or efficacy concerns in the submitted data. The FDA also said the resubmission must address Fabrazyme’s status as an available therapy.
- Following a September 2021 Type A meeting, the FDA agreed in principle that the proposed clinical package could potentially support traditional approval. The company planned a BLA resubmission in the second half of 2022, including final two-year BALANCE analyses. The filing gives no assurance of approval or a firm approval timetable.
- The EMA validated the PRX-102 marketing authorization application in February 2022. This is a post-year-end development, not a 2021 result.
- Interim BALANCE results announced in June 2021 were mixed: the lower confidence bound missed the prespecified non-inferiority margin in the primary ITT analysis set but was above it in the per-protocol set. Final results were expected in 2022. BRIDGE and BRIGHT were completed; the filing describes BRIGHT findings as generally stable disease measures and acceptable tolerability.
- Management said year-end funds were sufficient for at least 12 months from issuance of the financial statements, while also noting potential need for additional capital. Funding sources may include collaborations, licensing, equity or debt; financing could be dilutive. The company raised approximately $40.2 million gross in a February 2021 stock offering and $8.8 million gross through its prior ATM program.
- In August 2021, the company exchanged $54.65 million principal amount of 2021 notes for $28.75 million of 2024 notes plus cash; remaining 2021 notes were paid at maturity in November. The exchange resulted in a reported $0.8 million extinguishment loss.
- Fiocruz has not met certain purchase commitments under the Brazil supply agreement. The company reported $6.4 million of Brazilian product sales in 2021 and retains a termination right, but continued supplying the product while discussing compliance.
- Other significant risks include dependence on PRX-102 and partners Chiesi and Pfizer; regulatory and manufacturing inspection delays; competition and reimbursement uncertainty; reliance on some single-source materials; and Israeli operating, currency and government-grant restrictions. NATI grant-related contingent royalties were approximately $38.6 million at year-end, before interest, assuming the full amount is payable.
Most important facts for investors to verify
- PRX-102 regulatory progress: FDA inspection status, BLA resubmission timing and requirements, final BALANCE results, and the EMA review outcome.
- Cash runway and financing needs: confirm subsequent cash use, any additional funding, and compliance with the $7.5 million minimum-cash covenant.
- 2024 notes: principal, interest, conversion and dilution exposure, collateral terms, and any changes to covenant compliance.
- Revenue quality and sustainability: Chiesi-related license/R&D revenue recognition estimates, Pfizer supply sales, and Fiocruz purchase performance.
- Manufacturing readiness and costs, including FDA inspection findings and the effect of elevated inventories and 2021 manufacturing costs.